Sarah Cannon Research Institute | Strategic Alliance Partners

Benjamin Garmezy, MD discussed the potential of a GSPT1 molecular glue degrader and a trispecific T-cell engager in treating select prostate cancers.

Investigators are currently assessing the safety and preliminary activity of AVZO-103 among patients with advanced solid tumors in a phase 1/2 trial.

The safety profile of tucatinib plus trastuzumab and pertuzumab was consistent with the established profiles of each individual agent.

The next-generation ADC, CRB-701, demonstrated an emerging objective response rate of 57% in a subgroup of patients with HNSCC.

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

With the recent approvals of T-DXd and Dato-DXd, the care for breast cancer continues to evolve and expand.

Erika Hamilton, MD, gave an overview of evolving therapies and recent trial updates for patients across breast cancer subtypes.

The World Health Organization has approved emiltatug ledadotin as XMT-1660’s international nonproprietary name.